Barclays analyst Jack Meehan initiates coverage on Bio-Rad Labs (NYSE: BIO) with a Equalweight rating and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE